Moderna vaccine added to COVID-19 booster arsenal
A major study shows a booster dose of Moderna’s mRNA COVID-19 vaccine in a heterologous schedule increases immunogenicity compared with a homologous regime.
Neutralising antibodies are lower, however, with use of the Novavax protein-based vaccine as a booster.
The results are timely for GPs as the TGA announced on Wednesday it had provisionally approved the use of Moderna's Spikevax as a booster shot for adults following any of the primary courses approved in Australia.
The UK-based Com-COV2 study